Logo of cmrPermissionsJournals.ASM.orgJournalCMR ArticleJournal InfoAuthorsReviewers
Clin Microbiol Rev. 1999 Oct; 12(4): 554–563.

New Insights into Human Cryptosporidiosis


Cryptosporidium parvum is an important cause of diarrhea worldwide. Cryptosporidium causes a potentially life-threatening disease in people with AIDS and contributes significantly to morbidity among children in developing countries. In immunocompetent adults, Cryptosporidium is often associated with waterborne outbreaks of acute diarrheal illness. Recent studies with human volunteers have indicated that Cryptosporidium is highly infectious. Diagnosis of infection with this parasite has relied on identification of acid-fast oocysts in stool; however, new immunoassays or PCR-based assays may increase the sensitivity of detection. Although the mechanism by which Cryptosporidium causes diarrhea is still poorly understood, the parasite and the immune response to it probably combine to impair absorption and enhance secretion within the intestinal tract. Important genetic studies suggest that humans can be infected by at least two genetically distinct types of Cryptosporidium, which may vary in virulence. This may, in part, explain the clinical variability seen in patients with cryptosporidiosis.

An excellent review of cryptosporidiosis that summarized the history, classification, and life cycle of this parasite has previously appeared in this journal (30). The present article will serve as an update to that review and will focus on topics relevant to the clinical microbiologist, particularly those pertaining to human disease and to the Cryptosporidium species pathogenic to humans, Cryptosporidium parvum.

Cryptosporidium species are intracellular protozoan parasites that have emerged as an important cause of diarrhea among humans and animals. Cryptosporidium exists in the environment as a hearty, 5-μm-diameter oocyst, which contains four sporozoites. Humans and animals are infected by ingesting these oocysts, which travel through the gut lumen to the small intestine, where they rupture, releasing the sporozoites. The sporozoites are motile, 5- by 1-μm forms which adhere to and invade the absorptive epithelial cells which line the gastrointestinal tract. This invasion process is likely to involve molecules discharged from parasite organelles (rhoptries, micronemes, and dense granules) found in the apical end of the sporozoite. Thus, Cryptosporidium belongs to the phylum Apicomplexa, which contains its relatives, Toxoplasma, Eimeria, and Plasmodium. Soon after attachment and discharge of these organellar contents, Cryptosporidium focally disrupts the microvilli which cover the host cell and slides into the host cell, enveloping itself in the host cell membrane in the process. The parasite quickly establishes an intracellular niche which is unique to Cryptosporidium, in which the parasite and the surrounding parasitophorous vacuole bulge into the gut lumen and are separated from the host cell cytoplasm by a fascinating electron-dense structure. Here, the parasite replicates into eight merozoites, which then rupture out of the host cell, infect other host cells, and complete the asexual stage of the life cycle. At some point, merozoites differentiate into gamonts, which undergo sexual reproduction within the same host to ultimately regenerate oocysts, which are excreted in the feces (29, 37, 137, 138, 140).


HIV-Infected Individuals

Unlike immunocompetent adults, in whom cryptosporidiosis is usually self-limited, people with AIDS are susceptible to a devastating form of cryptosporidiosis manifested by chronic, voluminous diarrhea (46, 114, 119). The factors which predispose these people to chronic cryptosporidiosis rather than self-limited illness appear to be immunologic (118). While a human immunodeficiency virus (HIV)-positive individual may acquire cryptosporidiosis at any point in the viral infection, the most severe, chronic form is limited to people with markedly impaired immune systems. Flanigan et al. have found that patients with CD4 cell counts of greater than 180 cells/mm3 cleared the infection spontaneously whereas 87% of patients with CD4 cell counts less than 180 cells/mm3 had persistent disease (40).

Although AIDS-related cryptosporidiosis often manifests as a severe, persistent diarrheal illness, there is actually marked variability in the clinical presentation, including asymptomatic infection (10, 52, 62, 88, 116, 125, 153). Manabe et al. have identified four general clinical categories of AIDS-related cryptosporidiosis: a cholera-like illness requiring intravenous rehydration therapy (33%), a chronic diarrheal illness (36%), an intermittent diarrheal illness (15%), and a transient diarrheal illness (15%) (82). These clinical manifestations are independent of the general immune status, since all patients in this study were markedly immunosuppressed. In addition to the obvious morbidity associated with AIDS-related cryptosporidiosis, mortality is also increased (20, 27, 61, 82, 144).

Although the intestinal tract is the primary site of cryptosporidiosis, other involved organ systems have been described, including the lungs, middle ear, biliary tract, pancreas, and stomach (34, 43, 49, 78, 123, 136, 146). These sites most probably represent luminal extension of a primary infection of the intestine rather than a primary extraintestinal infection or a disseminated infection. The biliary tract is the most common, clinically relevant site of extraintestinal infection. Vakil et al. found that HIV-positive patients exposed to a waterborne outbreak of cryptosporidiosis were at increased risk for biliary symptoms and death within 1 year if their CD4 cell counts were <50 cells/mm3 (143).

Since the introduction of highly active antiretroviral therapy (HAART) to the treatment of HIV-infected individuals, the overall morbidity and mortality due to opportunistic infections has dramatically declined (111). Several studies have specifically documented a decreased prevalence of cryptosporidiosis subsequent to introduction of HAART (67, 75, 92). Also, it appears that reconstitution of immune system function with HAART may lead to the resolution of existing cryptosporidiosis in some patients (see “Treatment” below).

Children in Developing Countries

Cryptosporidium is a recognized cause of diarrhea, particularly among children, in developing countries (36, 77, 79, 93, 102104, 124, 126). Several studies have suggested that cryptosporidiosis is most common in children younger than 1 year and is associated with malnutrition. Because these studies were largely incidence studies, it was not clear if malnutrition predisposed children to cryptosporidiosis, if cryptosporidiosis led to malnutrition, or both. Checkley et al. observed a cohort of Peruvian children, aged 0 to 3 months on recruitment, for 2 years to address this question (22). The incidence of cryptosporidiosis in this cohort was high (45%); however, neither wasting nor low weight was a significant risk factor for cryptosporidiosis. Children with symptomatic cryptosporidiosis grew less during the first month of infection than did children without diarrhea who were not infected. Interestingly, this study identified a large percentage of asymptomatic infections (63%). The effect of asymptomatic cryptosporidiosis was less severe, but these children also gained less weight than the controls did. Consequently, this study suggests that cryptosporidiosis leads to malnutrition in previously normal children. The factors which determine whether a primary infection will be symptomatic or asymptomatic are undefined.

In a study of Brazilian children, Agnew et al. have identified a possible mechanism for malnutrition subsequent to cryptosporidiosis (2). In a case-control study of children monitored from birth, children younger than 1 year were found to experience excessive and protracted (nearly 2 years) episodes of diarrheal illness, which was not due to the initial episode or recurrent episodes of cryptosporidiosis. Only 14% of these children were initially coinfected with a second pathogen (including Salmonella species, Shigella flexneri, Ascaris lumbricoides, Trichuris trichiura, and Giardia lamblia). The mechanism of this subsequent diarrheal disease is unclear but may involve persistent malabsorption due to Cryptosporidium-induced intestinal injury or enhanced susceptibility to other enteric pathogens. Alternatively, immunologic abnormalities may be present in these children, analogous to the increased delayed mortality associated with high-titer measles vaccination in low socioeconomic populations.


A group of investigators in Texas has pioneered experimental studies of cryptosporidiosis in human volunteers. In their first study, 29 healthy adults, previously unexposed to C. parvum (seronegative), were challenged with different doses of the Iowa isolate of C. parvum. In these studies, the percentage of infected individuals (those subsequently excreting oocysts in stool) was directly related to the dose of oocysts administered, ranging from 20% for 30 oocysts to 100% for >1,000 oocysts. Of the 18 individuals who excreted oocysts, 11 had enteric symptoms and 7 had diarrhea plus one other enteric symptom (35). Volunteers with diarrheal illness tended to excrete more oocysts over the course of infection (21). Linear regression analysis determined that the median infectious dose was very low (132 oocysts). Trials comparing the infectious dose of three different isolates suggest that isolates may differ significantly in virulence (108).

To examine the susceptibility and serologic response to reinfection, 19 of the previously infected volunteers were rechallenged with 500 oocysts 1 year after the primary infection. Fewer subjects shed oocysts after the second exposure (16%), but the rates of diarrhea were similar, although the diarrhea was less clinically severe. The number of anti-Cryptosporidium immunoglobulin G (IgG) and IgA seroconversions increased after secondary exposure, but the serologic response did not correlate with symptoms or the presence of oocysts in the stool (109). Further studies examining serologic responses to specific Cryptosporidium antigens suggested that increases in specific antibody reactivity were more prevalent among symptomatic individuals and that persons with preexisting antibodies may be less likely to develop illness (101). Specifically, individuals with preexisting IgG antibody to a 27-kDa Cryptosporidium antigen excreted fewer oocysts than did those without this antibody. Also, IgG reactivity to a 17-kDa antigen and IgM reactivity to the 27-kDa antigen were higher prior to infection for asymptomatic individuals than for symptomatic individuals. Therefore, previous exposure of immunocompetent adults to Cryptosporidium is not entirely protective but may decrease the severity of disease and the number of oocysts shed.


The diagnosis of cryptosporidiosis rests on the identification of the 5-μm spherical oocysts (or oocyst components) in stool or the intracellular stages within biopsy specimens of human gastrointestinal mucosa. In tissue sections, a simple hematoxylin-and-eosin stain should suffice to identify the morphology of the intracellular life stages of the parasite in its unique apical location within the intestinal epithelial cell (47, 53, 74, 78). Mucosal biopsies may also identify important, treatable copathogens such as cytomegalovirus. In one study, the duodenal mucosa was infected in 93% of AIDS patients with cryptosporidiosis; consequently, this appears to be a reasonable site for biopsy in these patients (78).

A variety of diagnostic options are available for the detection of Cryptosporidium in clinical stool samples (Table (Table1).1). The particular assay used by a laboratory will depend on a number of factors, particularly cost containment and level of staff training. Auramine-rhodamine screening of stool sediment smears followed by modified Ziehl-Neelsen (acid-fast) staining is a sensitive and specific approach for the identification of Cryptosporidium oocysts in stool (81) and is utilized at my institution. Stringent morphologic criteria must be applied to the diagnosis to avoid confusion with other oocysts, such as Cyclospora oocysts, which are significantly larger (10 μm). While this assay is usually adequate to diagnose cryptosporidiosis in symptomatic HIV-infected individuals who are excreting billions of oocysts (9), additional sensitivity may be desirable when screening immunocompetent individuals, asymptomatic individuals, or environmental samples; consequently, additional tests have been developed to improve upon the acid-fast stain. It is also likely that cryptosporidiosis is underdiagnosed because clinicians fail to consider this diagnosis in patients with diarrheal illnesses (particularly immunocompetent adults and children) and do not request stool analysis for Cryptosporidium, a test not normally included in routine stool analysis. Ideally, laboratories should have ongoing communication with public health departments and water utilities in order to recognize outbreaks and should have mechanisms in place to screen all specimens for Cryptosporidium in such settings.

Diagnostic options for Cryptosporidium detection in clinical samples


Several immunofluorescence assay (IFA) kits that are commercially available for the detection of Cryptosporidium in stool and environmental samples are listed in Table Table2.2. Commercially available enzyme immunoassays (EIAs) for the detection of Cryptosporidium are also listed in Table Table2.2. A recent comparative study by Garcia and Shimizu found high EIA (ProSpecT [Alexon] and Meridian Premier Cryptosporidium [Meridian Diagnostics]) sensitivity (98 to 99%) and specificity (100%) compared with the Meridian MERIFLUOR Cryptosporidium/Giardia kit (45). All IFA results (TechLab, Meridian MERIFLUOR) gave similar results, with 100% sensitivity and specificity. Graczyk et al. have found that an EIA (ProSpecT [Alexon]) and two IFAs (MERIFLUOR and Hydrofluor [Ensys, Inc.]) were very sensitive for the detection of C. parvum (100%) but that both tests showed some cross-reactivity for non-parvum Cryptosporidium oocysts (54). While such cross-reactivity is probably not significant in clinical samples, it may misidentify Cryptosporidium species which are nonhuman pathogens within environmental samples (54).

Commercially available assays for Cryptosporidium detection


PCR-based detection of microbes in clinical samples is attractive due to its extreme sensitivity and specificity. Additionally, the genetic information obtained from the sample may permit nonhuman pathogens to be distinguished from human pathogens. Methods for PCR-based detection of Cryptosporidium in clinical samples and drinking water have recently been reviewed (44, 100, 150). Several published PCR-based detection systems for Cryptosporidium in stool are summarized in Table Table3.3. Some investigators have found high sensitivity for PCR-based assays (one oocyst) and suggest that these assays are more sensitive than microscopic analysis of acid-fast smears (98); unfortunately, no large comparative study has been performed to determine the ideal primers, PCR conditions, or stool extraction methods to use with clinical samples.

PCR-based methods for detection of Cryptosporidium in stool

Several factors complicate the PCR-based detection of C. parvum in stool. Standard fixation in 10% buffered formalin may reduce the sensitivity of the PCR, particularly if fixation occurs over an extended period. Also, extended formalin fixation may alter the buoyancy of C. parvum oocysts, interfering with standard methods for purification of C. parvum oocysts from stool. PCR detection of oocysts from frozen stool is also possible, but the sensitivity may be reduced, probably due to rupture of oocysts during thawing. One method for oocyst purification from stool commonly used in the research laboratory involves density gradient centrifugation of stool (135, 139). While this method provides purified oocysts, ideal for PCR analysis, it is more suitable for a research laboratory than a clinical laboratory and may not be useful for specimens containing few oocysts. The PCR can be inhibited by numerous substances, including some stool components. Several investigators have developed nucleic acid extraction methods for stool to remove these inhibitors (48, 76, 154). Unfortunately, many of these methods are quite complex, and detailed comparative studies have not been performed to identify the most useful technique.


One of the most biologically intriguing, and clinically frustrating, features of cryptosporidiosis is its resistance to antimicrobial drugs. Unlike many of its relatives (Toxoplasma gondii, Eimeria, and Plasmodium), there is no curative therapy for cryptosporidiosis, despite in vitro and in vivo testing of hundreds of compounds. One possible explanation for this is that Cryptosporidium establishes a compartment within the host cell, which is morphologically different from the setting used by the related parasites. This unique parasitophorous vacuole may somehow shelter the parasite from antimicrobial drugs (56).

Because the clinical course of cryptosporidiosis depends largely on the immune status of the host, treatment options vary accordingly (55). In immunocompetent adults and children, no specific therapy is indicated, since the disease is self-limiting; however, as in any diarrheal illness, hydration must be carefully monitored. In individuals with persistent diarrhea, an underlying immunodeficiency (HIV infection, congenital immunodeficiency, etc.) should be considered. In developing countries, children with cryptosporidiosis often have associated (or subsequent) malnutrition, which should be addressed.

In immunocompromised hosts, particularly AIDS patients with CD4 cell counts below 200/mm3, cryptosporidiosis can be life-threatening and must be treated aggressively. Initially, the nutritional, hydration, and electrolyte status of the patient should be assessed and corrected with intravenous hydration, if necessary. Antimotility agents, such as opiates and somatostatin analogues, may also be used. In people with AIDS, the ideal treatment involves partial restoration of immune function with HAART. Several case reports have demonstrated the resolution of cryptosporidial diarrhea coincident with a rise in CD4 cell count upon combination antiretroviral therapy (12, 14, 42). While laboratories should be poised to respond to cases of cryptosporidiosis among individuals failing to respond to HAART, we have seen few such cases; most of our cases of AIDS-related cryptosporidiosis occur in patients who have never received HAART.

If HAART therapy is not possible, several antibiotics that have some efficacy against Cryptosporidium (paromomycin, nitazoxanide, azithromycin) have been reported and should be considered. Of these, paromomycin has been the most widely used and has consistently displayed at least partial activity in experimental systems and clinical trials (39, 41, 139). A combination of paromomycin and azithromycin has also been proposed for the treatment of cryptosporidiosis (129). Other experimental therapies, like bovine hyperimmune colostrum, may also be considered (28). In patients with severe disease, infection with a copathogen such as cytomegalovirus should also be considered and treated.

Nitazoxanide (NTZ) is the latest drug to be widely tested against human cryptosporidiosis. NTZ is a nitrothiazole benzamide with broad antimicrobial activity. An open-label study of NTZ in 15 Mexican AIDS patients with cryptosporidiosis found parasite clearance in nearly 100% of patients, triggering larger studies in the United States (38). Another small, uncontrolled African study of NTZ also suggested that it has some efficacy (32). Unfortunately, one larger clinical trial and in vivo animal studies have been less encouraging (31, 139). Controlled clinical trials (ACTG 336) to determine the efficacy of NTZ in treating cryptosporidiosis are under way.

The best approach to prevention of cryptosporidiosis in HIV-infected individuals is the maintenance of immune system function by using HAART, since chronic cryptosporidiosis occurs only in severely immunosuppressed individuals. Also, it has been suggested that antibiotic regimens containing clarithromycin, aimed at preventing mycobacterial infections in severely immunosuppressed individuals, may inadvertently have a protective effect against cryptosporidiosis (60, 63). Avoidance of tap water has been touted in the AIDS community, but no clinical trial has confirmed the efficacy of this approach. Despite this, numerous commercial filters are available to remove oocysts from drinking water. Bottled water has also been advocated to prevent cryptosporidiosis, but few regulations are in place to guarantee these products.


In general, diarrhea develops when intestinal absorption is impaired or secretion is enhanced. Both of these processes are regulated by the intestinal epithelial cells which are infected by Cryptosporidium (26). Several investigators have identified impaired glucose-stimulated Na+ and H2O absorption and/or increased Cl secretion in experimental models of cryptosporidiosis (4, 5, 94). In addition to these transport defects, abnormalities in the barrier properties of the intestinal epithelium, mediated in part by intercellular junctional complexes, contribute to Cryptosporidium diarrhea. Two groups have found evidence of permeability defects and decreased resistance across C. parvum-infected intestinal cell lines (1, 57). In addition, both groups found that C. parvum infection of these monolayers resulted in the release of cytoplasmic lactate dehydrogenase, consistent with cellular injury, which ultimately resulted in cell death. Another group has suggested that Cryptosporidium induces apoptosis in biliary epithelial cells, but this mechanism of cell death has not been confirmed in vivo (25). Malabsorption and abnormal intestinal permeability (decreased vitamin B12 absorption, decreased d-xylose absorption, abnormal lactulose/mannitol permeability test) have been confirmed in people with AIDS and cryptosporidiosis (53, 133). One mechanism for the induction of intestinal secretion by Cryptosporidium may involve the stimulation of prostaglandin production by intestinal epithelial cells (70).



Like other protozoan parasites, Cryptosporidium appears incapable of de novo purine synthesis and relies on salvage pathways for hypoxanthine, guanine, and adenine. Studies with radiolabeled purine precursors (formate and glycine) indicate that these compounds are incorporated into host cells but not intracellular C. parvum. Enzymatic activity necessary for purine salvage (hypoxanthine, guanine, and xanthine phosphoribosyltransferase) was identified in C. parvum sporozoites and may localize to a single enzyme. Such an enzyme may serve as an antiparasitic drug target (33). Keithly et al. have identified a polyamine biosynthesis pathway in C. parvum which is found chiefly in plants and some bacteria but not mammalian cells (64). The lead enzyme of this pathway, arginine decarboxylase, is sensitive to a specific, irreversible arginine decarboxylase inhibitor, which reduces the intracellular growth of C. parvum. Another potential drug target is the shikimate pathway, in which (in plants) chorismate is converted to p-aminobenzoic acid, folate, and other aromatic compounds (121). Cryptosporidium and other Apicomplexan parasites were found to be sensitive to glyphosate, an inhibitor of the shikimate pathway. This inhibition also provides circumstantial evidence for the existence of a plastid-like organelle in Cryptosporidium, similar to that described for Plasmodium and Toxoplasma (68, 87).

Molecular Genetics

Karyotypic analysis suggests that C. parvum contains eight chromosomes, ranging in size from 0.945 to 2.2 Mb, giving a total haploid genome size of approximately 10.4 Mb (11, 59). Also, one group has identified a low-molecular-weight molecule which may correspond to the 35-kb circular, extrachromosomal DNAs (plastids) found in other Apicomplexan parasites (11).

Recently, significant progress has been made toward understanding the C. parvum genome through expressed sequence tag (EST) and genome sequence survey (GSS) DNA-sequencing projects, as well as a genome-mapping project. To date, the EST project has isolated and partially sequenced 567 ESTs, with 37% of the unique clones demonstrating significant homology to GenBank sequences. A summary of this data can be found on the World Wide Web (31a). Two projects to sequence random fragments of Cryptosporidium genomic DNA are under way. One project has determined the sequence of 1,507 fragments, totaling more than 888,000 bp of new sequence; 27% of these sequences demonstrated homology to GenBank sequences. The second GSS project has sequenced 654 fragments, totaling more than 324,700 bp, with 16% of the unique sequences demonstrating homology to GenBank sequences. In addition to these sequencing projects, a complete map of the eight C. parvum chromosomes has recently been completed (115). All of these projects will greatly facilitate future studies of this organism.

rRNA gene structure is central to the phylogenic classification and genotyping of microbial organisms; therefore, the recent characterization of the C. parvum rRNA gene organization by Le Blancq et al. was an important milestone in Cryptosporidium research (72). These investigators found that the small- and large-subunit rRNAs are 1.7 and 3.6 kb, respectively; a 151-bp putative 5.8S rRNA was also identified. Like other eukaryotes, the rDNA unit is arranged as a 5′ small-subunit rRNA–internal transcribed spacer 1 (ITS1)–5.8S rRNA–ITS2–large-subunit rRNA 3′ complex. There appear to be five copies of the rDNA per haploid genome, which are not organized in the conventional head-to-tail arrangement but, rather, are dispersed throughout the genome to at least three different chromosomes. Interestingly, there are two distinct types of rDNA units (four copies of type A and one copy of type B) which contain marked differences in the ITS regions. Knowledge of this intraorganismal heterogeneity is crucial when interpreting PCR-based genotyping of C. parvum isolates based on rRNA heterogeneity. Similar rDNA organization is found in the Apicomplexan protozoa Plasmodium, Babesia, and Theileria. In Plasmodium, the two classes of rRNAs are differentially expressed during the life cycle of the parasite. Such information on developmental expression is not yet available for C. parvum. Curiously, another Apicomplexan parasite, T. gondii, has an entirely different rDNA organization, containing multiple copies of tandemly arrayed rDNAs. The phylogenetic and biologic consequences of these differences have not been resolved.

C. parvum was recently found to contain two small extrachromosomal, cytoplasmic, virus-like double-stranded RNAs (65, 66). These RNAs (1,786 and 1,374 nucleotides) each contain a single open reading frame which encodes a putative RNA-dependent RNA polymerase and a protein with limited homology to mammalian mitogen-activated c-Jun NH2-terminal protein kinases, respectively. Virus-like particles were not observed within sporozoites by electron microscopy, but other data suggested that the RNAs may be unencapsidated. Although there are several examples of protozoan viruses which infect Giardia, Trichomonas, and Leishmania, these viruses do not resemble the C. parvum virus-like RNAs. To date, these RNAs have been identified in many laboratory isolates and commercial samples of C. parvum but have not been found in five non-C. parvum members of the genus (66).


Paralleling the clinical diversity of cryptosporidiosis is increasing evidence of molecular heterogeneity among C. parvum isolates. Western blot analysis of C. parvum oocyst antigens with a Cryptosporidium-specific monoclonal antibody revealed heterogeneity among several human, calf, and lamb isolates (105). A second study of C. parvum antigens also found heterogeneity among human isolates and between human and animal isolates when using polyclonal and monoclonal antibodies against C. parvum antigens in Western blots (106). Two-dimensional gel electrophoresis of C. parvum sporozoite proteins from five different isolates has revealed a 106-kDa peptide which differed in its isoelectric point in several of the isolates and a 40-kDa protein in one isolate which was not present in the others (89). Finally, isoenzyme typing of C. parvum isolates from different geographical locations revealed two isoenzymes of phosphoglucomutase and hexokinase which segregated according to human or animal origin (6).

Recent genetic studies of Cryptosporidium support the evidence of isolate diversity obtained by analysis of sporozoite proteins and suggest that there are at least two subtypes of human isolates. Restriction fragment length polymorphism (RFLP) analysis of C. parvum genomic DNA from three bovine and three human isolates revealed polymorphism between the human and bovine isolates and among the human isolates (110). Another technique, the random amplification of polymorphic DNA (RAPD) (149), has also revealed genetic heterogeneity among C. parvum isolates. According to one study, RAPD analysis of 25 C. parvum isolates revealed two genotypes; one genotype was unique to human isolates, while the other was found predominantly in isolates from calves and lambs (96). Another recent study examining five C. parvum isolates by RAPD also found genetic heterogeneity among human and animal isolates (15). Finally, RFLP analysis of a repetitive DNA sequence in 23 human and calf C. parvum isolates revealed the same profile in all calf isolates but two patterns among the human isolates, one of which was identical to the profiles in the calf isolates (13). Sequence analysis of three C. parvum genes (encoding dihydrofolate reductase-thymidylate synthase, α-tubulin, and β-tubulin) from a calf isolate and a human isolate has also identified an unexpectedly high level of polymorphism (145).

More recently, several investigators have used RFLP and DNA sequencing of polymorphic genes to determine the genotype of larger numbers of C. parvum isolates from animals, humans infected in outbreaks, and people with AIDS. These studies continue to support the concept that humans can be infected by two genetically distinct types of Cryptosporidium, designated genotype 1 (human type) and genotype 2 (bovine type). The results of several recent studies are summarized in Table Table4.4. These studies suggest that cattle are exclusively infected by genotype 2 isolates and that most human infections are caused by genotype 1 parasites. Several of the human infections caused by genotype 2 isolates appear to be zoonotic, with an identifiable bovine source. Unfortunately, division of C. parvum isolates into two discrete groups is probably an oversimplification. First, several investigators have found evidence of isolates containing a mixture of genotype 1 and genotype 2 alleles (16). Second, multilocus genotype determination has failed to identify recombinant genotypes, suggesting that most genotype 1 and genotype 2 isolates are reproductively isolated populations (130); however, the same investigators have identified polymorphism in the β-tubulin gene intron which might have arisen from a recombination event (151). Although these studies have contributed significantly to our understanding of genetic diversity among Cryptosporidium isolates, most have been small studies with geographically diverse isolates from sporadic outbreaks. Larger studies focused on specific populations, such as people with AIDS or children in developing countries, are necessary before we can have a more complete understanding of the molecular epidemiology of cryptosporidiosis.

Genotyping of human Cryptosporidium isolates

Several investigators have speculated that Cryptosporidium isolates may also vary in virulence, in part explaining the clinical diversity observed in cryptosporidiosis. One study has suggested that genotype 1 isolates are less virulent than genotype 2 isolates in in vitro assays measuring the disruption of intestinal cell monolayers (monolayer resistance and cytoplasmic lactate dehydrogenase release) (152). Also, experimental data indicates that the host ranges for genotype 1 and 2 isolates are different, with genotype 1 isolates being infectious mainly to humans and primates and genotype 2 isolates being infectious to most mammals (112, 117, 152).


Much of what is known about the immune response to Cryptosporidium has been learned from experimental murine models. While such models are useful, they have several limitations. First, immunocompetent adult mice are not susceptible to C. parvum infection. For unclear reasons, only immunocompetent mouse pups (younger than 26 days) are susceptible to infection (107). Second, few murine models completely mimic human infection, since infected mice do not typically develop diarrhea. Recent exceptions are the gamma interferon (IFN-γ) knockout mice, which can be infected by relatively few oocysts and will experience weight loss and wasting and eventually die (58, 90). Mice with severe combined immunodeficiency (SCID mice) are also susceptible to C. parvum infection, and have been widely used to study the immunology of cryptosporidiosis (86).

The two key immune components necessary for prevention and/or resolution of cryptosporidiosis as shown by these studies are CD4+ lymphocytes and IFN-γ (23, 24, 85, 113, 141). Depletion of IFN-γ by intraperitoneal injection of anti-IFN-γ antibodies resulted in a shortened prepatent period, increased oocyst excretion, and early disease and death (85). Also, a human case of protracted cryptosporidiosis in a patient with IFN-γ deficiency has been reported (51). Selective immune cell reconstitution experiments have defined an important role for CD4+ lymphocytes in the prevention or resolution of cryptosporidiosis (23, 85, 113) as well as a possible role for CD8+ lymphocytes (85). Similarly, mice which lack functional CD4+ lymphocytes (major histocompatibility complex class II-deficient mice) were more susceptible to infection than were control mice and were unable to clear the infection; CD8-deficient mice (major histocompatibility complex class I-deficient mice) resolved the infection (3). Also, mice deficient in T-cell receptor α (present on most CD4+ lymphocytes) were more susceptible to infection than were controls. Gamma/delta-T-cell-deficient neonatal mice were more susceptible than control mice but were able to clear the infection (147). Since the cytokine interleukin-12 can induce IFN-γ production, it is not surprising that treatment of mice with interleukin-12 prevented or greatly reduced the severity of infection (142). In experimental murine infections, neither tumor necrosis factor nor natural killer cells were important in resolving infection (24, 85, 122). The mechanisms by which Cryptosporidium-infected intestinal epithelial cells initiate immune responses are not entirely clear. One apparent mechanism in human cells involves the production of tumor necrosis factor alpha, interleukin-8, and C-X-C chemokines by infected mucosa (69, 127).


Outbreaks of cryptosporidiosis due to drinking-water contamination, including a massive outbreak in Milwaukee, Wis. (80), have been increasingly recognized. Several recent reviews have dealt with this important public health concern (44, 83, 128). There are four major factors that contribute to these outbreaks: (i) the prevalence of Cryptosporidium in source water is high; (ii) Cryptosporidium oocysts are refractory to chlorine treatment of drinking water; (iii) coarse filtration methods normally performed on surface drinking waters do not efficiently remove Cryptosporidium oocysts, due to their small diameter; and (iv) the infectious dose of Cryptosporidium for humans is extremely low (73). Although water treatment deficiencies have been identified in some outbreaks, at least one outbreak has occurred in association with a modern treatment facility where treatment was well documented and unremarkable (50). In the United States, routine testing of drinking water is mandatory for all surface water utilities serving populations of >100,000 persons; however, the current methods for Cryptosporidium detection may underestimate parasite numbers (44). In several situations, outbreaks were caused by contamination of recreational water in swimming pools and sprinklers (19, 84). In addition to drinking water, food contamination has been implicated in several outbreaks of cryptosporidiosis (17, 18, 91). Presumably these outbreaks were due to fecal contamination of food by infected animals or food workers. Such incidents may lead to increased regulation of potentially infected food products imported into the United States. In the future, sensitive PCR-based assays may facilitate the detection and genotyping of Cryptosporidium in environmental sources.


Cryptosporidium is a highly infectious cause of diarrheal illness around the world. The human host range is broad and includes people with AIDS, children in developing countries, and outbreaks among immunocompetent individuals. Within many of these groups, the manifestations of disease are diverse, ranging from asymptomatic infections to life-threatening illness. Recent evidence suggests that humans can be infected by at least two genetically different types of Cryptosporidium. This diversity may, in part, explain the clinical spectrum of cryptosporidiosis, but other factors, including host differences, are also likely to be important.


1. Adams R B, Guerrant R L, Zu S, Fang G, Roche J K. Cryptosporidium parvum infection of intestinal epithelium: Morphologic and functional studies in an in vitro model. J Infect Dis. 1994;169:170–177. [PubMed]
2. Agnew D G, Lima A A M, Newman R D, Wuhib T, Moore R D, Guerrant R L, Sears C L. Cryptosporidiosis in northeastern Brazilian children: association with increased diarrhea morbidity. J Infect Dis. 1998;177:754–760. [PubMed]
3. Aguirre S A, Mason P H, Perryman L E. Susceptibility of major histocompatibility complex (MHC) class I- and MHC class II-deficient mice to Cryptosporidium parvum infection. Infect Immun. 1994;62:697–699. [PMC free article] [PubMed]
4. Argenzio R A, Lecce J, Powell D W. Prostanoids inhibit intestinal NaCl absorption in experimental porcine cryptosporidiosis. Gastroenterology. 1993;104:440–447. [PubMed]
5. Argenzio R A, Liacos J A, Levy M L, Meuten D J, Lecce J G, Powell D W. Villous atrophy, crypt hyperplasia, cellular infiltration, and impaired glucose-Na absorption in enteric cryptosporidiosis of pigs. Gastroenterology. 1990;98:1129–1140. [PubMed]
6. Awad-El-Kariem F M, Robinson H A, Dyson D A, Evans D, Wright S, Fox M T, McDonald V M. Differentiation between human and animal strains of Cryptosporidium parvum using isoenzyme typing. Parasitology. 1995;110:129–132. [PubMed]
7. Awad-El-Kariem F M, Warhurst D C, McDonald V. Detection and species identification of Cryptosporidium oocysts using a system based on PCR and endonuclease restriction. Parasitology. 1994;109:19–22. [PubMed]
8. Balatbat A B, Jordan G W, Tang Y J, Silva J J. Detection of Cryptosporidium parvum DNA in human feces by nested PCR. J Clin Microbiol. 1996;34:1769–1772. [PMC free article] [PubMed]
9. Blackman E, Binder S, Gaultier C, Benveniste R, Cecilio M. Cryptosporidiosis in HIV-infected patients: diagnostic sensitivity of stool examination, based on number of specimens submitted. Am J Gastroenterol. 1997;92:451–453. [PubMed]
10. Blanshard C, Jackson A M, Shanson D C, Francis N, Gazzard B G. Cryptosporidiosis in HIV-seropositive patients. Q J Med. 1992;85:813–823. [PubMed]
11. Blunt D S, Khramtsov N V, Upton S J, Montelone B A. Molecular karyotype analysis of Cryptosporidium parvum: evidence for eight chromosomes and a low-molecular-size molecule. Clin Diagn Lab Immunol. 1997;4:11–13. [PMC free article] [PubMed]
12. Bobin S, Bouhour D, Durupt S, Boibieux A, Girault V, Peyramond D. Value of protease inhibitors in the treatment of infections due to microsporidium and/or Cryptosporidium in patients with the HIV. Pathol Biol. 1998;46:418–419. [PubMed]
13. Bonnin A, Fourmaux M N, Dubremetz J F, Nelson R G, Gobet P, Harly G, Buisson M, Puygauthier-Toubsas D, Gabriel-Pospisil F, Naciri M. Genotyping human and bovine isolates of Cryptosporidium parvum by polymerase chain reaction-restriction fragment length polymorphism analysis of a repetitive DNA sequence. FEMS Microbiol Lett. 1996;137:207–211. [PubMed]
14. Carr A, Marriott D, Field A, Vasak E, Cooper D A. Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet. 1998;351:256–261. [PubMed]
15. Carraway M, Tzipori S, Widmer G. Identification of genetic heterogeneity in the Cryptosporidium parvum ribosomal repeat. Appl Environ Microbiol. 1996;62:712–716. [PMC free article] [PubMed]
16. Carraway M, Tzipori S, Widmer G. A new restriction fragment length polymorphism from Cryptosporidium parvum identifies genetically heterogeneous parasite populations and genotypic changes following transmission from bovine to human hosts. Infect Immun. 1997;65:3958–3960. [PMC free article] [PubMed]
17. Centers for Disease Control and Prevention. Foodborne outbreak of diarrheal illness associated with Cryptosporidium parvum—Minnesota. Morbid Mortal Weekly Rep. 1995;45:783–784. [PubMed]
18. Centers for Disease Control and Prevention. Foodborne outbreak of cryptosporidiosis—Spokane, Washington, 1997. Morbid Mortal Weekly Rep. 1998;47:565–567. [PubMed]
19. Centers for Disease Control and Prevention. Outbreak of cryptosporidiosis associated with a water sprinkler fountain—Minnesota, 1997. Morbid Mortal Weekly Rep. 1998;47:856–860. [PubMed]
20. Chaisson R E, Gallant J E, Keruly J C, Moore R D. Impact of opportunistic disease on survival in patients with HIV infection. AIDS. 1998;12:29–33. [PubMed]
21. Chappell C L, Okhuysen P C, Sterling C R, DuPont H L. Cryptosporidium parvum: intensity of infection and oocyst excretion patterns in healthy volunteers. J Infect Dis. 1996;173:232–236. [PubMed]
22. Checkley W, Gilman R H, Epstein L D, Suarez M, Diaz J F, Cabrera L, Black R E, Sterling C R. Asymptomatic and symptomatic cryptosporidiosis: their acute effect on weight gain in Peruvian children. Am J Epidemiol. 1997;145:156–163. [PubMed]
23. Chen W, Harp J A, Harmsen A G. Requirements for CD4+ cells and gamma interferon in resolution of established Cryptosporidium parvum infection in mice. Infect Immun. 1993;61:3928–3932. [PMC free article] [PubMed]
24. Chen W, Harp J A, Harmsen A G, Havell E A. Gamma interferon functions in resistance to Cryptosporidium parvum infection in severe combined immunodeficient mice. Infect Immun. 1993;61:3548–3551. [PMC free article] [PubMed]
25. Chen X M, Levine S A, Tietz P, Krueger E, Mcniven M A, Jefferson D M, Mahle M, Larusso N F. Cryptosporidium parvum is cytopathic for cultured human biliary epithelia via an apoptotic mechanism. Hepatology. 1998;28:906–913. [PubMed]
26. Clark D P, Sears C L. The pathogenesis of cryptosporidiosis. Parasitol Today. 1996;12:221–225. [PubMed]
27. Colford J M, Jr, Tager I B, Hirozawa A M, Lemp G F, Aragon T, Petersen C. Cryptosporidiosis among patients infected with human immunodeficiency virus. Factors related to symptomatic infection and survival. Am J Epidemiol. 1996;144:807–816. [PubMed]
28. Crabb J H. Antibody-based immunotherapy of cryptosporidiosis. Adv Parasitol. 1998;40:121–149. [PubMed]
29. Current W L. Cryptosporidiosis. JAMA. 1985;187:1334–1338. [PubMed]
30. Current W L, Garcia L S. Cryptosporidiosis. Clin Microbiol Rev. 1991;4:325–358. [PMC free article] [PubMed]
31. Davis L J, Soave R E, Dudley R E, Fessel J W, Faulkner S, Mamaxos J P. Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C.: American Society for Microbiology; 1996. Nitazoxanide (NTZ) for AIDS-related cryptosporidial diarrhea (CD): an open-label safety, efficacy and pharmacologic study; p. 289.
31a. Davis, R. W., R. W. Hyman, R. G. Nelson, and W. B. Strong. 15 March 1999, posting date. Sequences. [Online.] http://medsfgn.ucsf.edu/id/CpDemoProj/index.html. [21 July 1999, last date accessed.]
32. Doumbo O, Rossignol J F, Richard E, Traore H A, Diakite D M, Traore F, Diallo D A. Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa. Am J Trop Med Hyg. 1997;56:637–639. [PubMed]
33. Doyle P S, Kanaani J, Wang C C. Hypoxanthine, guanine, xanthine phosphoribosyltransferase activity in Cryptosporidium parvum. Exp Parasitol. 1998;89:9–15. [PubMed]
34. Dunand V A, Hammer S M, Rossi R, Poulin M, Albrecht M A, Doweiko J P, DeGirolami P C, Coakley E, Piessens E, Wanke C A. Parasitic sinusitis and otitis in patients infected with human immunodeficiency virus: report of five cases and review. Clin Infect Dis. 1997;25:267–272. [PubMed]
35. DuPont H L, Chappell C L, Sterling C R, Okhuysen P C, Rose J B, Jakubowski W. The infectivity of Cryptosporidium parvum in healthy volunteers. N Engl J Med. 1995;332:855–859. [PubMed]
36. Enriquez F J, Avila C R, Santos J I, Tanaka-Kido J, Vallejo O, Sterling C R. Cryptosporidium infections in Mexican children: clinical, nutritional, enteropathogenic, and diagnostic evaluations. Am J Trop Med Hyg. 1997;56:254–257. [PubMed]
37. Fayer R, Ungar B L P. Cryptosporidium spp. and cryptosporidiosis. Microbiol Rev. 1986;50:458–483. [PMC free article] [PubMed]
38. Feregriuno G M, Higuera R F, Rossignol J F, Cavier R, Villarreal C, Padierna O J, Hidalgo H. XI International Conference on AIDS. 1996. Extraordinary potency of the Nitozoxanida, a new antiparasitary against the Cryptosporidium infections in advanced AIDS, abstr. Th.B.4213.
39. Fichtenbaum C J, Ritchie D J, Powderly W G. Use of paromomycin for treatment of cryptosporidiosis in patients with AIDS. Clin Infect Dis. 1993;16:298–300. [PubMed]
40. Flanigan T, Whalen C, Turner J, Soave R, Toerner J, Havlir D, Kotler D. Cryptosporidium infection and CD4 counts. Ann Intern Med. 1992;116:840–842. [PubMed]
41. Flanigan T P, Ramratnam B, Graeber C, Hellinger J, Smith D, Wheeler D, Hawley P, Heath-Chiozzi M, Ward D J, Brummitt C. Prospective trial of paromomycin for cryptosporidiosis in AIDS. Am J Med. 1996;100:370–372. [PubMed]
42. Foudraine N A, Weverling G J, van Gool T, Roos M T L, de Wolf F, Koopmans P P, van den Broek P J, Meenhorst P L, van Leeuwen R, Lange J M A. Improvement of chronic diarrhoea in patients with advanced HIV-1 infection during potent antiretroviral therapy. AIDS. 1998;12:35–41. [PubMed]
43. French A L, Beaudet L M, Benator D A, Levy C S, Kass M, Orenstein J M. Cholecystectomy in patients with AIDS: clinicopathologic correlations in 107 cases. Clin Infect Dis. 1995;21:852–858. [PubMed]
44. Fricker C R, Crabb J H. Water-borne cryptosporidiosis: detection methods and treatment options. Adv Parasitol. 1998;40:241–278. [PubMed]
45. Garcia L S, Shimizu R Y. Evaluation of nine immunoassay kits (enzyme immunoassay and direct fluorescence) for detection of Giardia lamblia and Cryptosporidium parvum in human fecal specimens. J Clin Microbiol. 1997;35:1526–1529. [PMC free article] [PubMed]
46. Gellin B G, Soave R. Coccidian infections in AIDS. Toxoplasmosis, cryptosporidiosis, and isosporiasis. Med Clin North Am. 1992;76:205–234. [PubMed]
47. Genta R M, Chappell C L, White J A C, Kimball K T, Goodgame R W. Duodenal morphology and intensity of infection in AIDS-related intestinal cryptosporidiosis. Gastroenterology. 1993;105:1769–1775. [PubMed]
48. Gobet P, Buisson J C, Vagner O, Naciri M, Grappin M, Comparot S, Harly G, Aubert D, Varga I, Camerlynck P. Detection of Cryptosporidium parvum DNA in formed human feces by a sensitive PCR-based assay including uracil-N-glycosylase inactivation. J Clin Microbiol. 1997;35:254–256. [PMC free article] [PubMed]
49. Godwin T A. Crytosporidiosis in the acquired immunodeficiency syndrome: a study of 15 autopsy cases. Hum Pathol. 1991;22:1215–1224. [PubMed]
50. Goldstein S, Juranek D, Ravenholt O, Hightower A, Martin D, Mesnik J, Griffiths S, Bryant A, Reich R, Herwaldt B. Cryptosporidiosis: an outbreak association with drinking water despite state-of-the-art water treatment. Ann Intern Med. 1996;124:459–468. [PubMed]
51. Gomez Morales M A, Ausiello C M, Guarino A, Urbani F, Spagnuolo M I, Oignata C, Pozio E. Severe, protracted intestinal cryptosporidiosis associated with interferon γ deficiency: pediatric case report. Clin Infect Dis. 1996;22:848–850. [PubMed]
52. Goodgame R W, Genta R M, White A C, Chappell C L. Intensity of infection in AIDS-associated cryptosporidiosis. J Infect Dis. 1993;167:704–709. [PubMed]
53. Goodgame R W, Kimball K, Ou C-N, White J A C, Genta R M, Lifschitz C H, Chappell C L. Intestinal function and injury in acquired immunodeficiency syndrome-related cryptosporidiosis. Gastroenterology. 1995;108:1075–1082. [PubMed]
54. Graczyk T K, Cranfield M R, Fayer R. Evaluation of commercial enzyme immunoassay (EIA) and immunofluorescent antibody (IFA) test kits for detection of Cryptosporidium oocysts of species other than Cryptosporidium parvum. Am J Trop Med Hyg. 1996;54:274–279. [PubMed]
55. Griffiths J K. Human cryptosporidiosis: epidemiology, transmission, clinical disease, treatment, and diagnosis. Adv Parasitol. 1998;40:37–85. [PubMed]
56. Griffiths J K, Balakrishnan R, Widmer G, Tzipori S. Paromomycin and geneticin inhibit intracellular Cryptosporidium parvum without trafficking through the host cell cytoplasm: implications for drug delivery. Infect Immun. 1998;66:3874–3883. [PMC free article] [PubMed]
57. Griffiths J K, Moore R, Dooley S, Keusch G T, Tzipori S. Cryptosporidium parvum infection of Caco-2 cell monolayers induces an apical monolayer defect, selectively increases transmonolayer permeability, and causes epithelial cell death. Infect Immun. 1994;62:4506–4514. [PMC free article] [PubMed]
58. Griffiths J K, Theodos C, Paris M, Tzipori S. The gamma interferon gene knockout mouse: a highly sensitive model for evaluation of therapeutic agents against Cryptosporidium parvum. J Clin Microbiol. 1998;36:2503–2508. [PMC free article] [PubMed]
59. Hays M P, Mosier D A, Oberst R D. Enhanced karyotype resolution of Cryptosporidium parvum by contour-clamped homogeneous electric fields. Vet Parasitol. 1995;58:273–280. [PubMed]
60. Holmberg S D, Moorman A C, VonBargen J C, Loveless M O, Ward D J, Navin T R. Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. JAMA. 1998;279:384–386. [PubMed]
61. Hoxie N J, Davis J P, Vergeront J M, Nashold R D, Blair K A. Cryptosporidiosis-associated mortality following a massive waterborne outbreak in Milwaukee, Wisconsin. Am J Public Health. 1997;87:2032–2035. [PMC free article] [PubMed]
62. Janoff E N, Limas C, Gebhard R L, Penley K A. Cryptosporidial carriage without symptoms in the acquired immunodeficiency syndrome (AIDS) Ann Intern Med. 1990;112:75–76. [PubMed]
63. Jordan W C. Clarithromycin prophylaxis against Cryptosporidium enteritis in patients with AIDS. J Natl Med Assoc. 1996;88:425–427. [PMC free article] [PubMed]
64. Keithly J S, Zhu G, Upton S J, Woods K M, Martinez M P, Yarlett N. Polyamine biosynthesis in Cryptosporidium parvum and its implications for chemotherapy. Mol Biochem Parasitol. 1997;88:35–42. [PubMed]
65. Khramtsov N V, Upton S J. High-temperature inducible cell-free transcription and replication of double-stranded RNAs within the parasitic protozoan Cryptosporidium parvum. Virology. 1998;245:331–337. [PubMed]
66. Khramtsov N V, Woods K M, Nesterenko M V, Dykstra C C, Upton S J. Virus-like, double-stranded RNAs in the parasitic protozoan Cryptosporidium parvum. Mol Microbiol. 1997;26:289–300. [PubMed]
67. Kim L S, Hadley W K, Stansell J, Cello J P, Koch J. Declining prevalence of cryptosporidiosis in San Francisco. Clin Infect Dis. 1998;27:655–656. [PubMed]
68. Kohler S, Delwiche C F, Denny P W, Tilney L G, Webster P, Wilson R J M, Palmer J D, Roos D S. A plastid of probable green algal origin in apicomplexan parasites. Science. 1997;275:1485–1489. [PubMed]
69. Laurent F, Eckmann L, Savidge T, Morgan G, Theodos C, Naciri M, Kagnoff M. Cryptosporidium parvum infection of human intestinal epithelial cells induces the polarized secretion of C-X-C chemokines. Infect Immun. 1997;65:5067–5073. [PMC free article] [PubMed]
70. Laurent F, Kagnoff M F, Savidge T C, Naciri M, Eckmann L. Human intestinal epithelial cells respond to Cryptosporidium parvum infection with increased prostaglandin H synthase 2 expression and prostaglandin E2 and F production. Infect Immun. 1998;66:1787–1790. [PMC free article] [PubMed]
71. Laxer M L, Timblin B K, Patel R J. DNA sequences for the specific detection of Cryptosporidium parvum by the polymerase chain reaction. Am J Trop Med Hyg. 1991;45:688–694. [PubMed]
72. LeBlancq S M, Khramtsov N V, Zamani F, Upton S J, Wu T W. Ribosomal RNA gene organization in Cryptosporidium parvum. Mol Biochem Parasitol. 1997;90:463–478. [PubMed]
73. LeChevallier M W, Norton W D. Giardia and Cryptosporidium in raw and finished water. J Am Water Works Assoc. 1995;87(Sept.):54–68.
74. Lefkowitch J H, Krumholz S, Feng-Chen K-C, Griffin P, Despommier D, Brasitus T A. Cryptosporidiosis of the human small intestine: a light and electron microscopic study. Hum Pathol. 1984;15:746–752. [PubMed]
75. Lemoing V, Bissuel F, Costagliola D, Eid Z, Chapuis F, Molina J M, Salmonceron D, Brasseur P, Leport C. Decreased prevalence of intestinal cryptosporidiosis in HIV-infected patients concomitant to the widespread use of protease inhibitors. AIDS. 1998;12:1395–1397. [PubMed]
76. Leng X, Mosier D A, Oberst R D. Simplified method for recovery and PCR detection of Cryptosporidium DNA from bovine feces. Appl Environ Microbiol. 1996;62:643–647. [PMC free article] [PubMed]
77. Lima A A M, Fang G, Schorlin J B, de Albuquerque L, McAuliffe J F, Mota S, Leite R, Guerrant R L. Persistent diarrhea in Northeast Brazil: etiologies and interactions with malnutrition. Acta Paediatr Suppl. 1992;361:39–44. [PubMed]
78. Lumadue J A, Manabe Y C, Moore R D, Belitsos P C, Sears C L, Clark D P. A clinicopathologic analysis of AIDS-related cryptosporidiosis. AIDS. 1998;12:2459–2466. [PubMed]
79. Macfarlane D E, Horner-Bryce J. Cryptosporiodiosis in well nourished and malnourished children. Acta Paediatr Scand. 1987;76:474–477. [PubMed]
80. MacKenzie W R, Schell W L, Blair K A, Addiss D G, Peterson D E, Hoxie N J, Kazmierczak J J, Davis J P. Massive outbreak of waterborne Cryptosporidium infection in Milwaukee, Wisconsin: recurrence of illness and risk of secondary transmission. Clin Infect Dis. 1995;21:57–62. [PubMed]
81. MacPherson D W, McQueen R. Cryptosporidiosis: Multiattribute evaluation of six diagnostic methods. J Clin Microbiol. 1993;31:198–202. [PMC free article] [PubMed]
82. Manabe Y C, Clark D P, Moore R D, Lumadue J A, Dahlman H R, Belitsos P C, Chaisson R E, Sears C L. Cryptosporidiosis in patients with AIDS: correlates of disease and survival. Clin Infect Dis. 1998;27:536–542. [PubMed]
83. Marshall M M, Naumovitz D, Ortega Y, Sterling C R. Waterborne protozoan pathogens. Clin Microbiol Rev. 1997;10:67–85. [PMC free article] [PubMed]
84. McAnulty J M, Fleming D W, Gonzalez A H. A community-wide outbreak of cryptosporidiosis associated with swimming at a wave pool. JAMA. 1994;272:1597–1600. [PubMed]
85. McDonald V, Bancroft G J. Mechanisms of innate and acquired resistance to Cryptosporidium parvum infection in SCID mice. Parasite Immunol. 1994;16:315–320. [PubMed]
86. McDonald V, Deer R, Uni S, Iseki M, Bancroft G J. Immune responses to Cryptosporidium muris and Cryptosporidium parvum in adult immunocompetent or immunocompromised (nude and SCID) mice. Infect Immun. 1992;60:3325–3331. [PMC free article] [PubMed]
87. McFadden G I, Reith M E, Munholland J, Lang-Unnasch N. Plastid in human parasites. Nature. 1996;381:482. [PubMed]
88. McGowan I, Hawkins A S, Weller I V D. The natural history of cryptosporidial diarrhoea in HIV-infected patients. AIDS. 1993;7:349–354. [PubMed]
89. Mead J R, Humphreys R C, Sammons D W, Sterling C R. Identification of isolate-specific sporozoite proteins of Cryptosporidium parvum by two-dimensional gel electrophoresis. Infect Immun. 1990;58:2071–2075. [PMC free article] [PubMed]
90. Mead J R, You X D. Susceptibility differences to Cryptosporidium parvum infection in two strains of gamma interferon knockout mice. J Parasitol. 1998;84:1045–1048. [PubMed]
91. Millard P S, Gensheimer K F, Addiss D G, Sosin D M, Beckett G A, Houck-Jankoski A, Hudson A. An outbreak of cryptosporidiosis from fresh-pressed apple cider. JAMA. 1994;272:1592–1596. [PubMed]
92. Miller J R. Decreasing cryptosporidiosis among HIV-infected persons in New York City, 1995–1997. J Urban Health. 1998;75:601–602. [PubMed]
93. Molbak K, Andersen M, Aaby P, Hojlyng N, Jakobsen M, Sodemann M, daSilva A P J. Cryptosporidium infection in infancy as a cause of malnutrition: a community study from Guinea-Bissau, West Africa. Am J Clin Nutr. 1997;65:149–152. [PubMed]
94. Moore R, Tzipori S, Griffiths J K, Johnson K, DeMontigny L, Lomakina I. Temporal changes in permeability and structure of piglet ileum after site-specific infection by Cryptosporidium parvum. Gastroenterology. 1995;108:1030–1039. [PubMed]
95. Morgan U M, Constantine C C, Forbes D A, Thompson R C A. Differentiation between human and animal isolates of Cryptosporidium parvum using rDNA sequencing and direct PCR analysis. J Parasitol. 1997;83:825–830. [PubMed]
96. Morgan U M, Constantine C C, O’Donoghue P, Meloni B P, O’Brien P A, Thompson R C A. Molecular characterization of Cryptosporidium isolates from humans and other animals using random amplified polymorphic DNA analysis. Am J Trop Med Hyg. 1995;52:559–564. [PubMed]
97. Morgan U M, O’Brien P A, Thompson R C A. The development of diagnostic PCR primers for Cryptosporidium using RAPD-PCR. Mol Biochem Parasitol. 1996;77:103–108. [PubMed]
98. Morgan U M, Pallant L, Dwyer B W, Forbes D A, Rich G, Thompson R C A. Comparison of PCR and microscopy for detection of Cryptosporidium parvum in human fecal specimens: clinical trial. J Clin Microbiol. 1998;36:995–998. [PMC free article] [PubMed]
99. Morgan U M, Sargent K D, Deplazes P, Forbes D A, Spano F, Hertzberg H, Elliot A, Thompson R C A. Molecular characterization of Cryptosporidium from various hosts. Parasitology. 1998;117:31–37. [PubMed]
100. Morgan U M, Thompson R C A. PCR detection of Cryptosporidium: the way forward? Parasitol Today. 1998;14:241–246. [PubMed]
101. Moss D M, Chappell C L, Okhuysen P C, DuPont H L, Arrowood M J, Hightower A W, Lammie P J. The antibody response to 27-, 17-, and 15-kDa Cryptosporidium antigens following experimental infection in humans. J Infect Dis. 1998;178:827–833. [PubMed]
102. Neill M A, Rice S K, Admad N V, Flanigan T P. Cryptosporidiosis: an unrecognized cause of diarrhea in elderly hospitalized patients. Clin Infect Dis. 1996;22:168–170. [PubMed]
103. Newman R D, Wuhib T, Lima A A M, Guerrant R L, Sears C L. Environmental sources of Cryptosporidium in an urban slum in Northeastern Brazil. Am J Trop Med Hyg. 1993;49:270–275. [PubMed]
104. Newman R D, Zu S-X, Wuhib T, Lima A A M, Guerrant R L, Sears C L. Household epidemiology of Cryptosporidium parvum infection in an urban community in Northeast Brazil. Ann Intern Med. 1994;120:500–505. [PubMed]
105. Nichols G L, McLauchlin J, Samuel D. A technique for typing Cryptosporidium isolates. J Protozool. 1991;38:237S–240S. [PubMed]
106. Nina J M, McDonald V, Deer R M A, Wright S E, Dyson D A, Chiodini P L, McAdam K P W J. Comparative study of the antigenic composition of oocyst isolates of Cryptosporidium parvum from different hosts. Parasite Immunol. 1992;14:227–232. [PubMed]
107. Novak S M, Sterling C R. Susceptibility dynamics in neonatal BALB/c mice infected with Cryptosporidium parvum. J Protozool. 1991;38:102S–104S. [PubMed]
108. Okhuysen P C, Chappell C L, Sterling C R, DuPont H L. 35th Annual Meeting of the Infectious Diseases Society of America. 1997. Virulence of three distinct C. parvum isolates in healthy adults, abstr. 396.
109. Okhuysen P C, Chappell C L, Sterling C R, Jakubowski W, DuPont H L. Susceptibility and serologic response of healthy adults to reinfection with Cryptosporidium parvum. Infect Immun. 1998;66:441–443. [PMC free article] [PubMed]
110. Ortega Y R, Sheehy R R, Cama V A, Oishi K K, Sterling C R. Restriction fragment length polymorphism analysis of Cryptosporidium parvum isolates of bovine and human origin. J Protozool. 1991;38:40S–41S. [PubMed]
111. Palella F J, Delaney K M, Moorman A C, Loveless M O, Fuhrer J, Satten G A, Aschman D J, Holmberg S D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860. [PubMed]
112. Peng M P, Xiao L, Freeman A R, Arrowood M J, Escalante A A, Weltman A C, Ong C S L, MacKenzie W R, Lal A A, Beard C B. Genetic polymorphism among Cryptosporidium parvum isolates: evidence of two distinct human transmission cycles. Emerg Infect Dis. 1997;3:567–573. [PMC free article] [PubMed]
113. Perryman L E, Mason P H, Chrisp C E. Effect of spleen cell populations on resolution of Cryptosporidium parvum infection in SCID mice. Infect Immun. 1994;62:1474–1477. [PMC free article] [PubMed]
114. Petersen C. Cryptosporidiosis in patients infected with the human immunodeficiency virus. Clin Infect Dis. 1992;15:903–909. [PubMed]
115. Piper M B, Bankier A T, Dear P H. Construction and characterisation of a genomic PAC library of the intestinal parasite Cryptosporidium parvum. Mol Biochem Parasitol. 1998;95:147–151. [PubMed]
116. Pitlik S D, Fainstein V, Garza D, Guarda L, Bolivar R, Rios A, Hopfer R L, Mansell P A. Human cryptosporidiosis: spectrum of disease. Report of six cases and review of the literature. Arch Intern Med. 1983;143:2269–2275. [PubMed]
117. Pozio E, Morales M A G, Barbieri F M, La Rosa G. Cryptosporidium: different behavior in calves of isolates of human origin. Trans R Soc Trop Med Hyg. 1992;86:636–638. [PubMed]
118. Pozio E, Rezza G, Boschini A, Pezzotti P, Tamburrini A, Rossi P, Di Fine M, Smacchia C, Schiesare A, Gattei E. Clinical cryptosporidiosis and human immunodeficiency virus (HIV)-induced immunosuppression: findings from a longitudinal study of HIV-positive and HIV-negative former infection drug users. J Infect Dis. 1997;176:969–975. [PubMed]
119. Ramratnam B, Flanigan T P. Cryptosporidiosis in persons with HIV infection. Postgrad Med J. 1997;73:713–716. [PMC free article] [PubMed]
120. Ranucci L, Muller H, LaRosa G, Reckman I, Morales M A G, Spano F, Pozio E, Crisanti A. Characterization and immunolocalization of a Cryptosporidium protein containing repeated amino acid motifs. Infect Immun. 1993;61:2347–2356. [PMC free article] [PubMed]
121. Roberts F, Roberts C W, Johnson J J, Kyle D E, Krell T, Coggins J R, Coombs G H, Milhous W K, Tzipori S, Ferguson D J P. Evidence for the shikimate pathway in apicomplexan parasites. Nature. 1998;393:801–805. [PubMed]
122. Rohlman V C, Kuhis T L, Mosier D A, Crawford D L, Greenfield R A. Cryptosporidium parvum infection after abrogation of natural killer cell activity in normal and severe combined immunodeficiency mice. J Parasitol. 1993;79:295–297. [PubMed]
123. Rossi P, Rivasi F, Codeluppi M, Catania A, Tamburrini A, Righi E, Pozio E. Gastric involvement in AIDS associated cryptosporidiosis. Gut. 1998;43:476–477. [PMC free article] [PubMed]
124. Sallon S, Deckelbaum R J, Schmid I I, Harlap S, Baras M, Spira D T. Cryptosporidium, malnutrition, and chronic diarrhea in children. Am J Dis Child. 1988;142:312–315. [PubMed]
125. Saltzberg D M, Kotloff K L, Newman J L, Fastiggi R. Cryptosporidium infection in acquired immunodeficiency syndrome: not always a poor prognosis. J Clin Gastroenterol. 1991;13:94–97. [PubMed]
126. Sarabia-Arce S, Salazar-Lindo E, Gilman R H, Naranjo J, Miranda E. Case-control study of Cryptosporidium parvum infection in Peruvian children hospitalized for diarrhea: possible association with malnutrition and nosocomical infection. Pediatr Infect Dis J. 1990;9:627–631. [PubMed]
127. Seydel K B, Zhang T, Champion G A, Fichtenbaum C, Swanson P E, Tzipori S, Griffiths J K, Stanley J. Cryptosporidium parvum infection of human intestinal xenografts in SCID mice induces production of human tumor necrosis factor alpha and interleukin-8. Infect Immun. 1998;66:2379–2382. [PMC free article] [PubMed]
128. Smith H V, Rose J B. Waterbourne cryptosporidiosis: current status. Parasitol Today. 1998;14:14–22. [PubMed]
129. Smith N H, Cron S, Valdez L M, Chappell C L, White A C. Combination drug therapy for cryptosporidiosis in AIDS. J Infect Dis. 1998;178:900–903. [PubMed]
130. Spano F, Putignani L, Crisanti A, Sallicandro P, Morgan U M, LeBlancq S M, Tchack L, Tzipori S, Widmer G. A multilocus genotypic analysis of Cryptosporidium parvum from different hosts and geographical origin. J Clin Microbiol. 1998;36:3255–3259. [PMC free article] [PubMed]
131. Spano F, Putignani L, Guida S, Crisanti A. Cryptosporidium parvum: PCR-RFLP analysis of the TRAP-C1 (thrombospondin-related adhesive protein of Cryptosporidium-1) gene discriminates between two alleles differentially associated with parasite isolates of animal and human origin. Exp Parasitol. 1998;90:195–198. [PubMed]
132. Spano F, Putignani L, McLauchlin J, Casemore D P, Crisanti A. PCR-RFLP analysis of Cryptosporidium oocyst wall protein (COWP) gene discriminates between C. wrairi and C. parvum, and between C. parvum isolates of human and animal origin. FEMS Microbiol Lett. 1997;150:209–217. [PubMed]
133. Stockman M, Fromm M, Schmitz H, Schmidt W, Riecken E-O, Schulzke J-D. Duodenal biopsies of HIV-infected patients with diarrhoea exhibit epithelial barrier defects but no active secretion. AIDS. 1998;12:43–51. [PubMed]
134. Sulaiman I, Xiao L, Yang C, Escalente L, Moore A, Beard C, Arrowood M, Lal A. Differentiating human from animal isolates of Cryptosporidium parvum. Emerg Infect Dis. 1998;4:681–685. [PMC free article] [PubMed]
135. Taghi-Kilani R, Sekla L. Purification of Cryptosporidium parvum oocysts and sporozoites by cesium chloride and percoll gradients. Am J Trop Med Hyg. 1987;36:505–508. [PubMed]
136. Travis W D, Schmidt K, MacLowry J D, Masur H, Condron K S, Fojo A T. Respiratory cryptosporidiosis in a patient with malignant lymphoma. Report of a case and review of the literature. Arch Pathol Lab Med. 1990;114:519–522. [PubMed]
137. Tzipori S. Cryptosporidiosis in animals and humans. Microbiol Rev. 1983;47:84–96. [PMC free article] [PubMed]
138. Tzipori S. Cryptosporidiosis in perspective. Adv Parasitol. 1988;27:63–129. [PubMed]
139. Tzipori S. Cryptosporidiosis: laboratory investigations and chemotherapy. Adv Parasitol. 1998;40:187–221. [PubMed]
140. Tzipori S, Griffiths J K. Natural history and biology of Cryptosporidium parvum. Adv Parasitol. 1998;40:6–36. [PubMed]
141. Ungar B L P, Kao T-C, Burris J A, Finkelman F D. Cryptosporidium infection in an adult mouse model. Independent roles for IFN-γ and CD4+ T lymphocytes in protective immunity. J Immunol. 1991;147:1014–1022. [PubMed]
142. Urban J F, Jr, Fayer R, Chen S-J, Gause W C, Gately M K, Finkelman F D. IL-12 protects immunocompetent and immunodeficient neonatal mice against infection with Cryptosporidium parvum. J Immunol. 1996;156:263–268. [PubMed]
143. Vakil N B, Schwartz S M, Buggy B P, Brummitt C F, Kherellah M, Letzer D M, Gilson I H, Jones P G. Biliary cryptosporidiosis in HIV-infected people after the waterborne outbreak of cryptosporidiosis in Milwaukee. N Eng J Med. 1996;334:19–23. [PubMed]
144. Valdez H, Durke D, Gordon S M, Adal K A, Johnson J H, Wiest P M. Survival of AIDS patients with cryptosporidiosis. Infect Dis Clin Pract. 1998;7:157–160.
145. Vasquez J R, Gooze L, Kim K, Gut J, Petersen C, Nelson R G. Potential antifolate resistance determinants and genotypic variation in the bifunctional dihydrofolate reductase-thymidylate synthase gene from human and bovine isolates of Cryptosporidium parvum. Mol Biochem Parasitol. 1996;79:153–165. [PubMed]
146. Ventura G, Cauda R, Larocca L M, Riccioni M E, Tumbarello M, Lucia M B. Gastric cryptosporidiosis complicating HIV infection: case report and review of the literature. Eur J Gastroenterol Hepatol. 1997;9:307–310. [PubMed]
147. Waters W R, Harp J A. Cryptosporidium parvum infection in T-cell receptor (TCR)-α- and TCR-γ-deficient mice. Infect Immun. 1996;64:1854–1857. [PMC free article] [PubMed]
148. Webster K A, Pow J D E, Giles M, Catchpole J, Woodward M J. Detection of Cryptosporidium parvum using a specific polymerase chain reaction. Vet Parasitol. 1993;50:35–44. [PubMed]
149. Welsh J, McClelland M. Characterization of pathogenic microorganisms by genomic fingerprinting using arbitrarily primed PCR. In: Persing D H, Smith T F, Tenover F C, White T J, editors. Diagnostic molecular microbiology: principles and applications. Washington, D.C.: American Society for Microbiology; 1993. pp. 595–602.
150. Widmer G. Genetic heterogeneity and PCR detection of Cryptosporidium parvum. Adv Parasitol. 1998;40:223–240. [PubMed]
151. Widmer G, Tchack L, Chappell C L, Tzipori S. Sequence polymorphism in the β-tubulin gene reveals heterogeneous and variable population structures in Cryptosporidium parvum. Appl Environ Microbiol. 1998;64:4477–4481. [PMC free article] [PubMed]
152. Widmer G, Tzipori S, Fichtenbaum C J, Griffiths J K. Genotypic and phenotype characterization of Cryptosporidium parvum isolates from people with AIDS. J Infect Dis. 1998;178:834–840. [PubMed]
153. Zar F, Geeseler P J, Brown V A. Asymptomatic carriage of Cryptosporidium in the stool of a patient with acquired immunodeficiency syndrome. J Infect Dis. 1985;151:195. [PubMed]
154. Zhu G, Marchewka M J, Ennis J G, Keithly J S. Direct isolation of DNA from patient stools for polymerase chain reaction detection of Cryptosporidium parvum. J Infect Dis. 1998;177:1443–1446. [PubMed]

Articles from Clinical Microbiology Reviews are provided here courtesy of American Society for Microbiology (ASM)
PubReader format: click here to try


Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem chemical compound records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records. Multiple substance records may contribute to the PubChem compound record.
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...